UGT2B11 and prostate cancer: Combined with CCLE, GDSC and CTRP database, results showed that mRNA (CYP1A1, CYP3A4, UGT1A1, UGT1A8, UGT1A10, UGT2B7, UGT2B11, UGT2B17), miRNA (hsa-miR-612), lncRNA (GAS5, JPX, XIST, CCDC18-AS1), methylation (CYP1A1, CYP2B6, GAS5, SNH6) affected the IC50, EC50 and AUCs of antineoplastic drugs in prostate cancer cell lines.